KaloBios Pharma (KBIO) Tops Q2 EPS by 22c
Tweet
Share
E-mailGet Alerts KBIO Hot Sheet
Join SI Premium – FREE
KaloBios Pharma (NASDAQ: KBIO) reported Q2 EPS of ($1.46), $0.22 better than the analyst estimate of ($1.68).
For earnings history and earnings-related data on KaloBios Pharma (KBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Dare Bioscience (DARE) Tops Q2 EPS by 11c
- Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
